Conference Presentation
Tetra Therapeutics Shares Their BPN14770 Trials
August 29, 2022
00 h 09 m
Chad Coberly, CEO of Tetra Therapeutics, a Shionogi Group Company, presented about BPN14770, a PDE4 inhibitor, during the Industry Updates keynote session at the 18th International Fragile X Conference.
About the Webinar
With Chad Coberly
Chad Coberly, CEO of Tetra Therapeutics, a Shionogi Group Company, presented about BPN14770, a PDE4 inhibitor, during the Industry Updates keynote session at the 18th International Fragile X Conference. BPN14770 is in Phase 2b/3 trials in Fragile X syndrome to become an FDA-approved treatment for cognition in FXS.
Chad discussed the status of Tetra’s Fragile X program, including its Phase 2 trial results, current Phase 2b/3 BPN14770 trials, and hopeful approval timeline.
Related Webinars and Videos
